Related Experiment Video
Updated: Jun 17, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases
David G Nathan1, Stuart H Orkin
1Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.
Abstract:
The lysosomal storage diseases, such as Gaucher's disease, mucopolysaccharidosis I, II and IV, Fabry's disease, and Pompe's disease, are rare inherited disorders whose symptoms result from enzyme deficiency causing lysosomal accumulation. Until effective gene-replacement therapy is developed, expensive, and at best incomplete, enzyme-replacement therapy is the only hope for sufferers of rare lysosomal storage diseases. Preventive strategies involving carrier detection should be a priority toward the successful management of these conditions.
Related Concept Videos
Lysosomal Hydrolases
Gene Therapy
Gene Therapy
Pharmacogenomics: Identification of New Drug Targets
Microorganisms in Medicine and Therapeutics
Lysosomes

